Leighl, Natasha B.

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 6,198

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 3,713

Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet

Palliative Care and End-of-Life IssuesPalliative and Oncologic Care

Cited by 1,781

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H. A., Chadwick, D., Zuzarte, P. C., Borgida, A., Wang, T. T., Li, T., et al. (2018) · Nature

Cancer Genomics and DiagnosticsEpigenetics and DNA Methylation

Cited by 983

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 811

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 683

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 643

Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis

Hagerty, R. G., Butow, P. N., Ellis, P. M., Lobb, E. A., Pendlebury, S. C., Leighl, N., Mac Leod, C., & Tattersall, M. H. N. (2005) · Journal of Clinical Oncology

Palliative Care and End-of-Life IssuesPatient-Provider Communication in Healthcare

Cited by 582

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology

Cancer survivorship and carePharmacovigilance and Adverse Drug Reactions

Cited by 497

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 492

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

Leighl, N. B., Rekhtman, N., Biermann, W. A., Huang, J., Mino-Kenudson, M., Ramalingam, S. S., West, H., Whitlock, S., & Somerfield, M. R. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 281

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 230

Evolution of symptom burden of advanced lung cancer over a decade

Sung, M. R., Patel, M. V., Djalalov, S., Le, L. W., Shepherd, F. A., Burkes, R. L., Feld, R., Lin, S., Tudor, R., & Leighl, N. B. (2017) · Clinical Lung Cancer

Cancer survivorship and carePalliative Care and End-of-Life Issues

Cited by 98

Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now

Partridge, A. H., Seah, D. S. E., King, T., Leighl, N. B., Hauke, R., Wollins, D. S., & Von Roenn, J. H. (2014) · Journal of Clinical Oncology

Palliative Care and End-of-Life IssuesPalliative and Oncologic Care

Cited by 91

The Use of Wearable Devices in Oncology Patients: A Systematic Review

Chow, R., Drkulec, H., Im, J. H. B., Tsai, J., Nafees, A., Kumar, S., Hou, T., Fazelzad, R., Leighl, N. B., Krzyzanowska, M., et al. (2024) · The Oncologist

Mobile Health and mHealth ApplicationsContext-Aware Activity Recognition Systems

Cited by 85

Sample features associated with success rates in population-based EGFR mutation testing

Shiau, C. J., Babwah, J. P., da Cunha Santos, G., Sykes, J. R., Boerner, S. L., Geddie, W. R., Leighl, N. B., Wei, C., Kamel-Reid, S., Hwang, D. M., et al. (2014) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 78

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 72

Barriers and Challenges to Global Clinical Cancer Research

Seruga, B., Sadikov, A., Cazap, E. L., Delgado, L. B., Digumarti, R., Leighl, N. B., Meshref, M. M., Minami, H., Robinson, E., Yamaguchi, N. H., et al. (2014) · The Oncologist

Health and Medical Research ImpactsGlobal Health and Surgery

Cited by 54

Access to Personalized Medicine: Factors Influencing the Use and Value of Gene Expression Profiling in Breast Cancer Treatment

Bombard, Y., Rozmovits, L., Trudeau, M., Leighl, N. B., Deal, K., & Marshall, D. A. (2014) · Current Oncology

Breast Cancer Treatment StudiesBRCA gene mutations in cancer

Cited by 30

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer

Tomasini, P., Mascaux, C., Jao, K., Labbe, C., Kamel-Reid, S., Stockley, T., Hwang, D. M., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2019) · Clinical Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 22